Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Aug;80(2):483–490. doi: 10.1172/JCI113096

Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

M R Wardell, S O Brennan, E D Janus, R Fraser, R W Carrell
PMCID: PMC442261  PMID: 3038959

Abstract

The primary structure of apolipoprotein E (apo E) was investigated in seven type III hyperlipoproteinemic patients with the apo E-2/2 phenotype. Six of the patients had identical two-dimensional tryptic peptide maps. These differed from the normal apo E3 map by the altered mobility of a single peptide. Amino acid analysis and sequencing showed that apo E2 in these patients had a substitution of 158 Arg----Cys. The presence of this mutation in six of the seven type III patients confirms that this is the most common form of apo E2. The seventh type III patient had a unique map with a new peptide resulting from a substitution of 136 Arg----Ser. He was heterozygous for this and for the more common apo E2 (158 Arg----Cys) variant. His very low-density lipoprotein contained approximately five times more apo E2 (136 Arg----Ser) than apo E2 (158 Arg----Cys), as determined by cysteamine treatment and peptide mapping. This new apo E2 mutant thus appears to contribute significantly to the patient's hyperlipidemia.

Full text

PDF
483

Images in this article

485Image
on p.485
485Image
on p.485
486Image
on p.486
486Image
on p.486
486Image
on p.486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bidlingmeyer B. A., Cohen S. A., Tarvin T. L. Rapid analysis of amino acids using pre-column derivatization. J Chromatogr. 1984 Dec 7;336(1):93–104. doi: 10.1016/s0378-4347(00)85133-6. [DOI] [PubMed] [Google Scholar]
  2. Brennan S. O. Absolute identification of Hb D-Los Angeles (beta121 Glu replaced by Gln). Hemoglobin. 1977;1(6):571–576. doi: 10.3109/03630267709003421. [DOI] [PubMed] [Google Scholar]
  3. Brennan S. O., Carrell R. W. alpha 1-Antitrypsin Christchurch, 363 Glu----Lys: mutation at the P'5 position does not affect inhibitory activity. Biochim Biophys Acta. 1986 Sep 5;873(1):13–19. doi: 10.1016/0167-4838(86)90183-4. [DOI] [PubMed] [Google Scholar]
  4. Brennan S. O., Tauro G. P., Melrose W. Haemoglobin Port Phillip alpha91 (FG3) Leu replaced by Pro, a new unstable haemoglobin. FEBS Lett. 1977 Sep 1;81(1):115–117. doi: 10.1016/0014-5793(77)80940-x. [DOI] [PubMed] [Google Scholar]
  5. Brennan S. O. The molecular abnormality of albumin Parklands: 365 Asp----His. Biochim Biophys Acta. 1985 Aug 23;830(3):320–324. doi: 10.1016/0167-4838(85)90289-4. [DOI] [PubMed] [Google Scholar]
  6. Breslow J. L., Zannis V. I., SanGiacomo T. R., Third J. L., Tracy T., Glueck C. J. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J Lipid Res. 1982 Nov;23(8):1224–1235. [PubMed] [Google Scholar]
  7. Chou P. Y., Fasman G. D. Conformational parameters for amino acids in helical, beta-sheet, and random coil regions calculated from proteins. Biochemistry. 1974 Jan 15;13(2):211–222. doi: 10.1021/bi00699a001. [DOI] [PubMed] [Google Scholar]
  8. Chou P. Y., Fasman G. D. Prediction of protein conformation. Biochemistry. 1974 Jan 15;13(2):222–245. doi: 10.1021/bi00699a002. [DOI] [PubMed] [Google Scholar]
  9. Easley C. W. Combinations of specific color reactions useful in the peptide mapping technique. Biochim Biophys Acta. 1965 Sep 13;107(2):386–388. doi: 10.1016/0304-4165(65)90147-9. [DOI] [PubMed] [Google Scholar]
  10. Fainaru M., Mahley R. W., Hamilton R. L., Innerarity T. L. Structural and metabolic heterogeneity of beta-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia. J Lipid Res. 1982 Jul;23(5):702–714. [PubMed] [Google Scholar]
  11. Ghiselli G., Gregg R. E., Zech L. A., Schaefer E. J., Brewer H. B., Jr Phenotype study of apolipoprotein E isoforms in hyperlipoproteinaemic patients. Lancet. 1982 Aug 21;2(8295):405–407. doi: 10.1016/s0140-6736(82)90439-1. [DOI] [PubMed] [Google Scholar]
  12. Ghiselli G., Schaefer E. J., Gascon P., Breser H. B., Jr Type III hyperlipoproteinemia associated with apolipoprotein E deficiency. Science. 1981 Dec 11;214(4526):1239–1241. doi: 10.1126/science.6795720. [DOI] [PubMed] [Google Scholar]
  13. Gregg R. E., Ghiselli G., Brewer H. B., Jr Apolipoprotein EBethesda: a new variant of apolipoprotein E associated with type III hyperlipoproteinemia. J Clin Endocrinol Metab. 1983 Nov;57(5):969–974. doi: 10.1210/jcem-57-5-969. [DOI] [PubMed] [Google Scholar]
  14. Gregg R. E., Zech L. A., Schaefer E. J., Brewer H. B., Jr Apolipoprotein E metabolism in normolipoproteinemic human subjects. J Lipid Res. 1984 Nov;25(11):1167–1176. [PubMed] [Google Scholar]
  15. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hager D. A., Burgess R. R. Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes. Anal Biochem. 1980 Nov 15;109(1):76–86. doi: 10.1016/0003-2697(80)90013-5. [DOI] [PubMed] [Google Scholar]
  17. Hartley B. S. Strategy and tactics in protein chemistry. Biochem J. 1970 Oct;119(5):805–822. doi: 10.1042/bj1190805f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Havekes L., de Wit E., Leuven J. G., Klasen E., Utermann G., Weber W., Beisiegel U. Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia. Hum Genet. 1986 Jun;73(2):157–163. doi: 10.1007/BF00291607. [DOI] [PubMed] [Google Scholar]
  19. Havel R. J., Kotite L., Kane J. P., Tun P., Bersot T. Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3. J Clin Invest. 1983 Jul;72(1):379–387. doi: 10.1172/JCI110978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hazzard W. R., Warnick G. R., Utermann G., Albers J. J. Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: relationship to dysbetalipoproteinemia and hyperlipidemia. Metabolism. 1981 Jan;30(1):79–88. doi: 10.1016/0026-0495(81)90223-7. [DOI] [PubMed] [Google Scholar]
  21. Hui D. Y., Innerarity T. L., Mahley R. W. Lipoprotein binding to canine hepatic membranes. Metabolically distinct apo-E and apo-B,E receptors. J Biol Chem. 1981 Jun 10;256(11):5646–5655. [PubMed] [Google Scholar]
  22. Innerarity T. L., Kempner E. S., Hui D. Y., Mahley R. W. Functional unit of the low density lipoprotein receptor of fibroblasts: a 100,000-dalton structure with multiple binding sites. Proc Natl Acad Sci U S A. 1981 Jul;78(7):4378–4382. doi: 10.1073/pnas.78.7.4378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Innerarity T. L., Mahley R. W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry. 1978 Apr 18;17(8):1440–1447. doi: 10.1021/bi00601a013. [DOI] [PubMed] [Google Scholar]
  24. Innerarity T. L., Weisgraber K. H., Arnold K. S., Rall S. C., Jr, Mahley R. W. Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem. 1984 Jun 10;259(11):7261–7267. [PubMed] [Google Scholar]
  25. Janus E. D., Grant S., Lintott C. J., Wardell M. R. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis. 1985 Nov;57(2-3):249–266. doi: 10.1016/0021-9150(85)90038-3. [DOI] [PubMed] [Google Scholar]
  26. Janus E. D., Grant S., Lintott C. J., Wardell M. R. Apolipoprotein E phenotypes in hyperlipidaemic patients and their implications for treatment. Atherosclerosis. 1985 Nov;57(2-3):249–266. doi: 10.1016/0021-9150(85)90038-3. [DOI] [PubMed] [Google Scholar]
  27. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  28. Mahley R. W., Innerarity T. L., Rall S. C., Jr, Weisgraber K. H. Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res. 1984 Dec 1;25(12):1277–1294. [PubMed] [Google Scholar]
  29. McLean J. W., Elshourbagy N. A., Chang D. J., Mahley R. W., Taylor J. M. Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant. J Biol Chem. 1984 May 25;259(10):6498–6504. [PubMed] [Google Scholar]
  30. Offord R. E. Electrophoretic mobilities of peptides on paper and their use in the determination of amide groups. Nature. 1966 Aug 6;211(5049):591–593. doi: 10.1038/211591a0. [DOI] [PubMed] [Google Scholar]
  31. Orkin S. H., Kazazian H. H., Jr, Antonarakis S. E., Ostrer H., Goff S. C., Sexton J. P. Abnormal RNA processing due to the exon mutation of beta E-globin gene. Nature. 1982 Dec 23;300(5894):768–769. doi: 10.1038/300768a0. [DOI] [PubMed] [Google Scholar]
  32. Pitas R. E., Innerarity T. L., Arnold K. S., Mahley R. W. Rate and equilibrium constants for binding of apo-E HDLc (a cholesterol-induced lipoprotein) and low density lipoproteins to human fibroblasts: evidence for multiple receptor binding of apo-E HDLc. Proc Natl Acad Sci U S A. 1979 May;76(5):2311–2315. doi: 10.1073/pnas.76.5.2311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Rall S. C., Jr, Weisgraber K. H., Innerarity T. L., Bersot T. P., Mahley R. W., Blum C. B. Identification of a new structural variant of human apolipoprotein E, E2(Lys146 leads to Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype. J Clin Invest. 1983 Oct;72(4):1288–1297. doi: 10.1172/JCI111085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rall S. C., Jr, Weisgraber K. H., Innerarity T. L., Mahley R. W. Identical structural and receptor binding defects in apolipoprotein E2 in hypo-, normo-, and hypercholesterolemic dysbetalipoproteinemia. J Clin Invest. 1983 Apr;71(4):1023–1031. doi: 10.1172/JCI110829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rall S. C., Jr, Weisgraber K. H., Innerarity T. L., Mahley R. W. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A. 1982 Aug;79(15):4696–4700. doi: 10.1073/pnas.79.15.4696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Rall S. C., Jr, Weisgraber K. H., Mahley R. W. Human apolipoprotein E. The complete amino acid sequence. J Biol Chem. 1982 Apr 25;257(8):4171–4178. [PubMed] [Google Scholar]
  37. Schonfeld G. Disorders of lipid transport--update 1983. Prog Cardiovasc Dis. 1983 Sep-Oct;26(2):89–108. doi: 10.1016/0033-0620(83)90025-7. [DOI] [PubMed] [Google Scholar]
  38. Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature. 1977 Oct 13;269(5629):604–607. doi: 10.1038/269604a0. [DOI] [PubMed] [Google Scholar]
  39. Utermann G., Pruin N., Steinmetz A. Polymorphism of apolipoprotein E. III. Effect of a single polymorphic gene locus on plasma lipid levels in man. Clin Genet. 1979 Jan;15(1):63–72. [PubMed] [Google Scholar]
  40. Wardell M. R., Suckling P. A., Janus E. D. Genetic variation in human apolipoprotein E. J Lipid Res. 1982 Nov;23(8):1174–1182. [PubMed] [Google Scholar]
  41. Warnick G. R., Mayfield C., Albers J. J., Hazzard W. R. Gel isoelectric focusing method for specific diagnosis of familial hyperlipoproteinemia type 3. Clin Chem. 1979 Feb;25(2):279–284. [PubMed] [Google Scholar]
  42. Weisgraber K. H., Innerarity T. L., Harder K. J., Mahley R. W., Milne R. W., Marcel Y. L., Sparrow J. T. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem. 1983 Oct 25;258(20):12348–12354. [PubMed] [Google Scholar]
  43. Weisgraber K. H., Innerarity T. L., Mahley R. W. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem. 1982 Mar 10;257(5):2518–2521. [PubMed] [Google Scholar]
  44. Weisgraber K. H., Rall S. C., Jr, Innerarity T. L., Mahley R. W., Kuusi T., Ehnholm C. A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1. J Clin Invest. 1984 Apr;73(4):1024–1033. doi: 10.1172/JCI111287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Weisgraber K. H., Rall S. C., Jr, Mahley R. W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem. 1981 Sep 10;256(17):9077–9083. [PubMed] [Google Scholar]
  46. Weisgraber K. H., Rall S. C., Jr, Mahley R. W., Milne R. W., Marcel Y. L., Sparrow J. T. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. J Biol Chem. 1986 Feb 15;261(5):2068–2076. [PubMed] [Google Scholar]
  47. Yamamoto T., Davis C. G., Brown M. S., Schneider W. J., Casey M. L., Goldstein J. L., Russell D. W. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell. 1984 Nov;39(1):27–38. doi: 10.1016/0092-8674(84)90188-0. [DOI] [PubMed] [Google Scholar]
  48. Yamamura T., Yamamoto A., Hiramori K., Nambu S. A new isoform of apolipoprotein E--apo E-5--associated with hyperlipidemia and atherosclerosis. Atherosclerosis. 1984 Feb;50(2):159–172. doi: 10.1016/0021-9150(84)90019-4. [DOI] [PubMed] [Google Scholar]
  49. Yamamura T., Yamamoto A., Sumiyoshi T., Hiramori K., Nishioeda Y., Nambu S. New mutants of apolipoprotein E associated with atherosclerotic diseases but not to type III hyperlipoproteinemia. J Clin Invest. 1984 Oct;74(4):1229–1237. doi: 10.1172/JCI111532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Zannis V. I., Breslow J. L. Genetic mutations affecting human lipoprotein metabolism. Adv Hum Genet. 1985;14:125-215, 383-6. doi: 10.1007/978-1-4615-9400-0_3. [DOI] [PubMed] [Google Scholar]
  51. Zannis V. I., Breslow J. L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 1981 Feb 17;20(4):1033–1041. doi: 10.1021/bi00507a059. [DOI] [PubMed] [Google Scholar]
  52. Zannis V. I., Just P. W., Breslow J. L. Human apolipoprotein E isoprotein subclasses are genetically determined. Am J Hum Genet. 1981 Jan;33(1):11–24. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES